Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs
To assess the conditions of prescriptions and tolerance of antiplatelet drugs (APD) in the elderly and to detail the parameters that influence the tolerance of these drugs. Prospective survey in a Department of Geriatric Medicine. Two hundred nineteen patients 70 years and older treated with one or...
Gespeichert in:
| Veröffentlicht in: | Fundamental & clinical pharmacology 2012-04, Vol.26 (2), p.307-313 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 313 |
|---|---|
| container_issue | 2 |
| container_start_page | 307 |
| container_title | Fundamental & clinical pharmacology |
| container_volume | 26 |
| creator | Cadiou, Gwénaëlle Adam, Magali Caussin, Marie Landrin, Isabelle Mariette, Natacha Capet, Corinne Mouton-Schleifer, Dominique Remy, Elise Kadri, Nadir Doucet, Jean |
| description | To assess the conditions of prescriptions and tolerance of antiplatelet drugs (APD) in the elderly and to detail the parameters that influence the tolerance of these drugs. Prospective survey in a Department of Geriatric Medicine. Two hundred nineteen patients 70 years and older treated with one or two APD prior to admission were included during 7 months in 2008. We recorded the type of APD, associated diseases, main associated or co‐prescribed drugs which could interact with APD and the bleeding adverse events including cutaneous bleeding. The mean age of the 219 patients was 84.5 ± 6.7 years (70–101 years), women 59.4%. Among patients 64.8% received aspirin (mainly 75 mg), 28.3% received clopidogrel and 6.8% received their combination; 16.9% of prescriptions were off‐label; 51.6% of patients had an associated disease and/or an associated drug which could have increased risk of bleeding event. Among the patients who received a gastric‐protective drug, the prescription followed the recommendations of the French Health Authority in 38.9%. We recorded bleeding events in 24.2% of patients at admission and in 18.3% of patients during the hospitalization. Bleeding events were significantly more frequent in patients treated with aspirin than clopidogrel (40.8 vs. 24.2%, P |
| doi_str_mv | 10.1111/j.1472-8206.2010.00915.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_926875704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>926875704</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4355-1233bfc36d1b943657265a78f688fac39a5db457faba1087b1863eb4784cf5913</originalsourceid><addsrcrecordid>eNqNkEuP0zAURi0EYsrAX0DeIFYpfsSPIDajiimg0cBieOwsx7kBFzfJ2IloxZ_HaUvZ4o0l3_Pde30QwpQsaT6vNktaKlZoRuSSkfxKSEXFcvcALc6Fh2hBlFQFrzS9QE9S2hBCFaHyMbpglJWUS7ZAv6-60Q_BjhBgxE2cvifsOzz-AAyhgRj2r_EQIbnoh9H3XcJ9O0KXGTsMsR-iz1FsuwZHaCYHDR77ANF2DnC9xzal3s1IgxufwCZIB_gw6Cl61NqQ4NnpvkSfr9_erd4VNx_X71dXN4UruRAFZZzXreOyoXVVcikUk8Iq3UqtW-t4ZUVTl0K1traUaFVTLTnUpdKla0VF-SV6eeybF76fII1m65ODEGwH_ZRMxaRWQpEyk_pIutinFKE1-YNbG_eGEjObNxszCzazYDObNwfzZpejz09DpnoLzTn4V3UGXpwAm5wN7ezIp3-ckEzmVpl7c-R--QD7_17AXK8-HePFMe7TCLtz3MafRiquhPl6uzbrD_ru9tsXajT_AzAgr5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>926875704</pqid></control><display><type>article</type><title>Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Cadiou, Gwénaëlle ; Adam, Magali ; Caussin, Marie ; Landrin, Isabelle ; Mariette, Natacha ; Capet, Corinne ; Mouton-Schleifer, Dominique ; Remy, Elise ; Kadri, Nadir ; Doucet, Jean</creator><creatorcontrib>Cadiou, Gwénaëlle ; Adam, Magali ; Caussin, Marie ; Landrin, Isabelle ; Mariette, Natacha ; Capet, Corinne ; Mouton-Schleifer, Dominique ; Remy, Elise ; Kadri, Nadir ; Doucet, Jean</creatorcontrib><description>To assess the conditions of prescriptions and tolerance of antiplatelet drugs (APD) in the elderly and to detail the parameters that influence the tolerance of these drugs. Prospective survey in a Department of Geriatric Medicine. Two hundred nineteen patients 70 years and older treated with one or two APD prior to admission were included during 7 months in 2008. We recorded the type of APD, associated diseases, main associated or co‐prescribed drugs which could interact with APD and the bleeding adverse events including cutaneous bleeding. The mean age of the 219 patients was 84.5 ± 6.7 years (70–101 years), women 59.4%. Among patients 64.8% received aspirin (mainly 75 mg), 28.3% received clopidogrel and 6.8% received their combination; 16.9% of prescriptions were off‐label; 51.6% of patients had an associated disease and/or an associated drug which could have increased risk of bleeding event. Among the patients who received a gastric‐protective drug, the prescription followed the recommendations of the French Health Authority in 38.9%. We recorded bleeding events in 24.2% of patients at admission and in 18.3% of patients during the hospitalization. Bleeding events were significantly more frequent in patients treated with aspirin than clopidogrel (40.8 vs. 24.2%, P < 0.05) and/or with an associated drug (OR = 2.36, 95% CI 1.34–4.14, P < 0.01) and/or an associated disease (OR = 1.22, 95% CI 1.01–3.42, P < 0.05). APD treatment was stopped in 28.8% of patients, mainly because lack of indication or bleeding adverse events. Off‐label prescriptions of APD were not rare in the elderly, and adverse events are frequent. The results of this preliminary study evoke that medical situations at increased risk of bleeding are perhaps insufficiently evaluated, either in case of prescription of associated drugs with increased bleeding risk or during the follow‐up of patients with associated diseases. Cutaneous bleeding events should be more taken into account in prospective studies.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/j.1472-8206.2010.00915.x</identifier><identifier>PMID: 21241362</identifier><identifier>CODEN: FCPHEZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject><![CDATA[Aged ; Aged, 80 and over ; antiplatelet drugs ; Aspirin - administration & dosage ; Aspirin - adverse effects ; Aspirin - therapeutic use ; Biological and medical sciences ; bleeding events ; Drug Interactions ; Drug Therapy, Combination ; elderly ; Female ; France ; Hemorrhage - chemically induced ; Hemorrhage - epidemiology ; Humans ; Male ; Medical sciences ; Off-Label Use - statistics & numerical data ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Practice Guidelines as Topic ; Practice Patterns, Physicians' - standards ; Practice Patterns, Physicians' - statistics & numerical data ; Prospective Studies ; Risk Factors ; Ticlopidine - administration & dosage ; Ticlopidine - adverse effects ; Ticlopidine - analogs & derivatives ; Ticlopidine - therapeutic use]]></subject><ispartof>Fundamental & clinical pharmacology, 2012-04, Vol.26 (2), p.307-313</ispartof><rights>2011 The Authors Fundamental and Clinical Pharmacology © 2011 Société Française de Pharmacologie et de Thérapeutique</rights><rights>2015 INIST-CNRS</rights><rights>2011 The Authors Fundamental and Clinical Pharmacology © 2011 Société Française de Pharmacologie et de Thérapeutique.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4355-1233bfc36d1b943657265a78f688fac39a5db457faba1087b1863eb4784cf5913</citedby><cites>FETCH-LOGICAL-c4355-1233bfc36d1b943657265a78f688fac39a5db457faba1087b1863eb4784cf5913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1472-8206.2010.00915.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1472-8206.2010.00915.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25626915$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21241362$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cadiou, Gwénaëlle</creatorcontrib><creatorcontrib>Adam, Magali</creatorcontrib><creatorcontrib>Caussin, Marie</creatorcontrib><creatorcontrib>Landrin, Isabelle</creatorcontrib><creatorcontrib>Mariette, Natacha</creatorcontrib><creatorcontrib>Capet, Corinne</creatorcontrib><creatorcontrib>Mouton-Schleifer, Dominique</creatorcontrib><creatorcontrib>Remy, Elise</creatorcontrib><creatorcontrib>Kadri, Nadir</creatorcontrib><creatorcontrib>Doucet, Jean</creatorcontrib><title>Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs</title><title>Fundamental & clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>To assess the conditions of prescriptions and tolerance of antiplatelet drugs (APD) in the elderly and to detail the parameters that influence the tolerance of these drugs. Prospective survey in a Department of Geriatric Medicine. Two hundred nineteen patients 70 years and older treated with one or two APD prior to admission were included during 7 months in 2008. We recorded the type of APD, associated diseases, main associated or co‐prescribed drugs which could interact with APD and the bleeding adverse events including cutaneous bleeding. The mean age of the 219 patients was 84.5 ± 6.7 years (70–101 years), women 59.4%. Among patients 64.8% received aspirin (mainly 75 mg), 28.3% received clopidogrel and 6.8% received their combination; 16.9% of prescriptions were off‐label; 51.6% of patients had an associated disease and/or an associated drug which could have increased risk of bleeding event. Among the patients who received a gastric‐protective drug, the prescription followed the recommendations of the French Health Authority in 38.9%. We recorded bleeding events in 24.2% of patients at admission and in 18.3% of patients during the hospitalization. Bleeding events were significantly more frequent in patients treated with aspirin than clopidogrel (40.8 vs. 24.2%, P < 0.05) and/or with an associated drug (OR = 2.36, 95% CI 1.34–4.14, P < 0.01) and/or an associated disease (OR = 1.22, 95% CI 1.01–3.42, P < 0.05). APD treatment was stopped in 28.8% of patients, mainly because lack of indication or bleeding adverse events. Off‐label prescriptions of APD were not rare in the elderly, and adverse events are frequent. The results of this preliminary study evoke that medical situations at increased risk of bleeding are perhaps insufficiently evaluated, either in case of prescription of associated drugs with increased bleeding risk or during the follow‐up of patients with associated diseases. Cutaneous bleeding events should be more taken into account in prospective studies.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>antiplatelet drugs</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - adverse effects</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>bleeding events</subject><subject>Drug Interactions</subject><subject>Drug Therapy, Combination</subject><subject>elderly</subject><subject>Female</subject><subject>France</subject><subject>Hemorrhage - chemically induced</subject><subject>Hemorrhage - epidemiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Off-Label Use - statistics & numerical data</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Practice Patterns, Physicians' - standards</subject><subject>Practice Patterns, Physicians' - statistics & numerical data</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Ticlopidine - administration & dosage</subject><subject>Ticlopidine - adverse effects</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - therapeutic use</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEuP0zAURi0EYsrAX0DeIFYpfsSPIDajiimg0cBieOwsx7kBFzfJ2IloxZ_HaUvZ4o0l3_Pde30QwpQsaT6vNktaKlZoRuSSkfxKSEXFcvcALc6Fh2hBlFQFrzS9QE9S2hBCFaHyMbpglJWUS7ZAv6-60Q_BjhBgxE2cvifsOzz-AAyhgRj2r_EQIbnoh9H3XcJ9O0KXGTsMsR-iz1FsuwZHaCYHDR77ANF2DnC9xzal3s1IgxufwCZIB_gw6Cl61NqQ4NnpvkSfr9_erd4VNx_X71dXN4UruRAFZZzXreOyoXVVcikUk8Iq3UqtW-t4ZUVTl0K1traUaFVTLTnUpdKla0VF-SV6eeybF76fII1m65ODEGwH_ZRMxaRWQpEyk_pIutinFKE1-YNbG_eGEjObNxszCzazYDObNwfzZpejz09DpnoLzTn4V3UGXpwAm5wN7ezIp3-ckEzmVpl7c-R--QD7_17AXK8-HePFMe7TCLtz3MafRiquhPl6uzbrD_ru9tsXajT_AzAgr5w</recordid><startdate>201204</startdate><enddate>201204</enddate><creator>Cadiou, Gwénaëlle</creator><creator>Adam, Magali</creator><creator>Caussin, Marie</creator><creator>Landrin, Isabelle</creator><creator>Mariette, Natacha</creator><creator>Capet, Corinne</creator><creator>Mouton-Schleifer, Dominique</creator><creator>Remy, Elise</creator><creator>Kadri, Nadir</creator><creator>Doucet, Jean</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201204</creationdate><title>Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs</title><author>Cadiou, Gwénaëlle ; Adam, Magali ; Caussin, Marie ; Landrin, Isabelle ; Mariette, Natacha ; Capet, Corinne ; Mouton-Schleifer, Dominique ; Remy, Elise ; Kadri, Nadir ; Doucet, Jean</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4355-1233bfc36d1b943657265a78f688fac39a5db457faba1087b1863eb4784cf5913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>antiplatelet drugs</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - adverse effects</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>bleeding events</topic><topic>Drug Interactions</topic><topic>Drug Therapy, Combination</topic><topic>elderly</topic><topic>Female</topic><topic>France</topic><topic>Hemorrhage - chemically induced</topic><topic>Hemorrhage - epidemiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Off-Label Use - statistics & numerical data</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Practice Patterns, Physicians' - standards</topic><topic>Practice Patterns, Physicians' - statistics & numerical data</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Ticlopidine - administration & dosage</topic><topic>Ticlopidine - adverse effects</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cadiou, Gwénaëlle</creatorcontrib><creatorcontrib>Adam, Magali</creatorcontrib><creatorcontrib>Caussin, Marie</creatorcontrib><creatorcontrib>Landrin, Isabelle</creatorcontrib><creatorcontrib>Mariette, Natacha</creatorcontrib><creatorcontrib>Capet, Corinne</creatorcontrib><creatorcontrib>Mouton-Schleifer, Dominique</creatorcontrib><creatorcontrib>Remy, Elise</creatorcontrib><creatorcontrib>Kadri, Nadir</creatorcontrib><creatorcontrib>Doucet, Jean</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental & clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cadiou, Gwénaëlle</au><au>Adam, Magali</au><au>Caussin, Marie</au><au>Landrin, Isabelle</au><au>Mariette, Natacha</au><au>Capet, Corinne</au><au>Mouton-Schleifer, Dominique</au><au>Remy, Elise</au><au>Kadri, Nadir</au><au>Doucet, Jean</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs</atitle><jtitle>Fundamental & clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2012-04</date><risdate>2012</risdate><volume>26</volume><issue>2</issue><spage>307</spage><epage>313</epage><pages>307-313</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><coden>FCPHEZ</coden><abstract>To assess the conditions of prescriptions and tolerance of antiplatelet drugs (APD) in the elderly and to detail the parameters that influence the tolerance of these drugs. Prospective survey in a Department of Geriatric Medicine. Two hundred nineteen patients 70 years and older treated with one or two APD prior to admission were included during 7 months in 2008. We recorded the type of APD, associated diseases, main associated or co‐prescribed drugs which could interact with APD and the bleeding adverse events including cutaneous bleeding. The mean age of the 219 patients was 84.5 ± 6.7 years (70–101 years), women 59.4%. Among patients 64.8% received aspirin (mainly 75 mg), 28.3% received clopidogrel and 6.8% received their combination; 16.9% of prescriptions were off‐label; 51.6% of patients had an associated disease and/or an associated drug which could have increased risk of bleeding event. Among the patients who received a gastric‐protective drug, the prescription followed the recommendations of the French Health Authority in 38.9%. We recorded bleeding events in 24.2% of patients at admission and in 18.3% of patients during the hospitalization. Bleeding events were significantly more frequent in patients treated with aspirin than clopidogrel (40.8 vs. 24.2%, P < 0.05) and/or with an associated drug (OR = 2.36, 95% CI 1.34–4.14, P < 0.01) and/or an associated disease (OR = 1.22, 95% CI 1.01–3.42, P < 0.05). APD treatment was stopped in 28.8% of patients, mainly because lack of indication or bleeding adverse events. Off‐label prescriptions of APD were not rare in the elderly, and adverse events are frequent. The results of this preliminary study evoke that medical situations at increased risk of bleeding are perhaps insufficiently evaluated, either in case of prescription of associated drugs with increased bleeding risk or during the follow‐up of patients with associated diseases. Cutaneous bleeding events should be more taken into account in prospective studies.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21241362</pmid><doi>10.1111/j.1472-8206.2010.00915.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0767-3981 |
| ispartof | Fundamental & clinical pharmacology, 2012-04, Vol.26 (2), p.307-313 |
| issn | 0767-3981 1472-8206 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_926875704 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over antiplatelet drugs Aspirin - administration & dosage Aspirin - adverse effects Aspirin - therapeutic use Biological and medical sciences bleeding events Drug Interactions Drug Therapy, Combination elderly Female France Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Male Medical sciences Off-Label Use - statistics & numerical data Pharmacology. Drug treatments Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Practice Guidelines as Topic Practice Patterns, Physicians' - standards Practice Patterns, Physicians' - statistics & numerical data Prospective Studies Risk Factors Ticlopidine - administration & dosage Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use |
| title | Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T06%3A55%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiplatelet%20drugs%20in%20the%20elderly:%20prescriptions%20often%20inappropriate%20and%20reduced%20tolerance%20by%20associated%20diseases%20and%20drugs&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Cadiou,%20Gw%C3%A9na%C3%ABlle&rft.date=2012-04&rft.volume=26&rft.issue=2&rft.spage=307&rft.epage=313&rft.pages=307-313&rft.issn=0767-3981&rft.eissn=1472-8206&rft.coden=FCPHEZ&rft_id=info:doi/10.1111/j.1472-8206.2010.00915.x&rft_dat=%3Cproquest_cross%3E926875704%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=926875704&rft_id=info:pmid/21241362&rfr_iscdi=true |